ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Barcelona, CT, ESP:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 155 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 161 other locations

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy (GANNON)

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using...

Enrolling
Adenocarcinoma of the Pancreas
Pancreas Cancer
Device: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
HistoSonics

Barcelona, Spain

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Barcelona, Spain and 82 other locations

Sotorasib Combined with First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma (PANSOTO)

objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma...

Begins enrollment in 1 month
Pancreatic Adenocarcinoma
Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

Phase 2

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Barcelona, Spain and 24 other locations

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabin...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Atezolizumab
Drug: Gemcitabine

Phase 2

NovoCure
NovoCure

Barcelona, Spain and 14 other locations

Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1)

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Barcelona, Spain and 13 other locations

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 43 other locations

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: zolbetuximab

Phase 3

Astellas
Astellas

Barcelona, Spain and 164 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Barcelona, Spain and 203 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems